Gall Matthew 4

What Happened

• Matthew Gall, Chief Financial Officer of Kalaris Therapeutics, was granted a derivative award on March 19, 2026: options covering 95,000 shares. The Form 4 reports the transaction price as $0.00, indicating no cash was paid at grant. This is an award (not an open‑market purchase or sale) and does not represent immediately tradable common stock.

Key Details

• Transaction date: 2026-03-19; filing date: 2026-03-20 (reported promptly).
• Security: derivative (option) to acquire 95,000 shares; reported amount $0.00 at grant.
• Vesting: 25% of the shares vest on March 19, 2027, with the remainder vesting in equal monthly installments thereafter over the four‑year schedule, subject to continuous service (footnote F1).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Transaction code: A (award/grant). No indication of a 10b5-1 plan, tax‑withholding sale, or late filing in the materials provided.

Context

• These are stock option awards: they give the holder the right to acquire shares in the future if/when vested and exercised; they are not the same as an immediate purchase of common stock. Such grants are common for executive compensation and are informative about company incentives but do not by themselves indicate immediate buying or selling of stock.